• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AstraZeneca

    < Previous 1 2 3 4 5 6 7 Next >
    CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Q1 2024 results
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FASENRA approved for treatment of children aged 6 to 11 with severe asthma
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative breast cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Datopotamab deruxtecan Biologics License Application accepted in the US for patients with previously treated advanced nonsquamous non-small cell lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca Full year and Q4 2023 Financial Results
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with metastatic HER2-positive solid tumors
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus transarterial chemoembolization (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases
    From AstraZeneca
    Via Business Wire
    Tickers AZN GRCL
    WAINUA™ (eplontersen) Granted First-Ever Regulatory Approval in the US for the Treatment of Adults With Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca to Acquire Icosavax, Including Potential First-in-class RSV and hMPV Combination Vaccine With Positive Phase II Data
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca advances scientific leadership in hematology at ASH 2023
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca launches Evinova, a health-tech business to accelerate innovation across the life sciences sector, the delivery of clinical trials and better health outcomes
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TRUQAP™ (capivasertib) plus fulvestrant approved in the US for patients with advanced HR-positive breast cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolization in EMERALD-1 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca to leverage its global industrial-scale manufacturing and digital capabilities to boost US renewable natural gas productivity
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.